FIBRIC ACID ANTILIPEMIC AGENTS

Course overview

FIBRIC ACIDS ARE FDA INDICATED TO TREAT PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA. THEY REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), TOTAL CHOLESTEROL, TRIGLYCERIDES, AND APOLIPOPROTEIN B AND INCREASE HIGH-DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C) IN ADULTS. FIBRIC ACIDS SHOULD BE USED IN CONJUNCTION WITH A RESTRICTION OF CHOLESTEROL AND FAT INTAKE AND EXERCISE IF THE RESPONSE TO DIET AND NONPHARMACOLOGICAL INTERVENTIONS ALONE HAS BEEN INADEQUATE. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, SIGNIFICANT ADVERSE EFFECTS, CONTRAINDICATIONS, MONITORING, AND TOXICITY OF FIBRATE DRUGS SO THAT PROVIDERS CAN DIRECT PATIENT THERAPY TO OPTIMAL OUTCOMES.